Evaluation of recombinant human vascular endothelial growth factor VEGF121-loaded poly-l-lactide microparticles as a controlled release delivery system
Vascular endothelial growth factor A (VEGF-A) is an important growth factor that plays a major role in angiogenesis. With different isoforms distributed in various tissues, the shortest isoform of VEGF-A is VEGF121, one of the physiologically functional variants next to VEGF165. It is well known that VEGF has a shorter half-life, and the stability of the protein must be considered in therapeutic aspects. Poly-l-lactide (PLA) microparticles can release the encapsulated protein in a sustained release mode. In this study, the VEGF121 gene was cloned and expressed in a prokaryotic expression system (Escherichia coli). The recombinant VEGF121 was encapsulated with PLA microparticles and studied in vitro and ex ovo for the sustained release mechanism. The PLA-VEGF microparticles and the recombinant VEGF121 were explored for their bioactivity in human umbilical vein endothelial cells (HUVEC). VEGF released in vitro from PLA microparticles on days 1, 20, and 30 showed remarkable biological activity compared to PBS-loaded PLA microparticles such as the ability of the cells to proliferate, migrate, and form tubes similar to recombinant VEGF121. Besides, PLA-VEGF microparticles and the recombinant VEGF121 were also tested for their proangiogenic action in embryonated eggs by chicken chorioallantoic membrane assay (CAM), and the effect was observed in both forms. This study suggests that PLA-loaded VEGF microparticles in a sustainable release format can be effectively used in proangiogenic therapy and reduce the adverse effects caused due to multiple dosages.
___
- Adair TH, Montani JP (2010). San Rafael, CA, USA: Morgan &
Claypool Life Sciences.
- Anugraha G, Madhumathi J, Jeya Prita PJ, Kaliraj P (2015).
Biodegradable poly-l-lactide based microparticles as controlled
release delivery system for filarial vaccine candidate antigens.
European Journal of Pharmacology 747: 174-180.
- Baeshen MN, Al-Hejin AM, Bora RS, Ahmed MM, Ramadan HA et
al. (2015). Production of Biopharmaceuticals in E. coli: Current
Scenario and Future Perspectives. Journal of Microbiology and
Biotechnology 25 (7): 953-962.
- Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP et al.
(2009). The role of vascular endothelial growth factor in wound
healing. Journal of Surgical Research 153: 347-358.
- Beckert S, Farrahi F, Aslam RS, Scheuenstuhl H, Konigsrainer A et al.
(2006). Lactate stimulates endothelial cell migration. Wound
Repair and Regeneration 14: 321-324.
- Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP (1998). Tissuespecific expression pattern of vascular endothelial growth
factor isoforms in the malignant transformation of lung and
colon. Human Pathology 29: 910-914.
- Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and
its receptors. Nature Medicine 9: 669-676.
- Ferrara N, Henzel WJ (1989). Pituitary follicular cells secrete a novel
heparin-binding growth factor specific for vascular endothelial
cells. Biochemical and Biophysical Research Communications
161: 851-858.
- Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target.
Nature 438: 967-974.
- Folkman J, Klagsbrun M (1987). Angiogenic factors. Science 235:
442-447.
- Formiga FR, Pelacho B, Garbayo E, Abizanda G, Gavira JJ et al. (2010).
Sustained release of VEGF through PLGA microparticles
improves vasculogenesis and tissue remodeling in an acute
myocardial ischemia-reperfusion model. Journal of Controlled
Release 147: 30-37
- Geng H, Song H, Qi J, Cui D (2011). Sustained release of VEGF from
PLGA nanoparticles embedded thermo-sensitive hydrogel
in full-thickness porcine bladder acellular matrix. Nanoscale
Research Letters 6: 312.
- Han FY, Thurecht KJ, Whittaker AK, Smith MT (2016). Bioerodable
PLGA-based microparticles for producing sustained-release
drug formulations and strategies for improving drug loading.
Frontiers in Pharmacology 7: 185.
- He Y, Li Z, Chen Z, Yu X, Ji Z et al. (2018). Effects of VEGF-ANG1-PLA nano-sustained release microspheres on proliferation
and differentiation of ADSCs. Cell Biology International 42:
1060-1068.
- Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ et al.
(2003). The VIVA trial: Vascular endothelial growth factor
in Ischemia for vascular angiogenesis. Circulation 107: 1359-
1365.
- Howie DW, Manthey B, Hay S, Vernon-Roberts B (1993). The synovial
response to intraarticular injection in rats of polyethylene wear
particles. Clinical Orthopaedics and Related Research 352-357.
- Huang JC, Liu DY, Dawood MY (1998). The expression of vascular
endothelial growth factor isoforms in cultured human
endometrial stromal cells and its regulation by 17betaoestradiol. Molecular Human Reproduction 4: 603-607.
- Jia Q, Xu L, Zha Q, Chi X, Li F et al. (2007). High level expression
of HLA-A*0203-BSP fusion protein in Escherichia coli and
construction of soluble HLA-A*0203 monomer and tetramer
loaded with Epstein-Barr virus peptide. Cellular & Molecular
Immunology 4: 301-308.
- Jung YW, Kim JO, Rah H, Kim JH, Kim YR et al. (2016). Genetic
variants of vascular endothelial growth factor are associated
with recurrent implantation failure in Korean women.
Reproductive BioMedicine Online 32: 190-196.
- Kaur J, Kumar A, Kaur J (2018). Strategies for optimization of
heterologous protein expression in E. coli: Roadblocks
and reinforcements. International Journal of Biological
Macromolecules 106: 803-822.
- Kazemi-Lomedasht F, Behdani M, Pooshang Bagheri K, Habibi
Anbouhi M, Abolhassani M et al. (2014). Expression and
purification of functional human vascular endothelial growth
factor-a121; the most important angiogenesis factor. Advanced
Pharmaceutical Bulletin 4: 323-328.
- Kim S, Mohamedali KA, Cheung LH, Rosenblum MG (2007).
Overexpression of biologically active VEGF121 fusion proteins
in Escherichia coli. Journal of Biotechnology 128: 638-647.
- Lee BK, Yun Y, Park K (2016). PLA micro- and nano-particles.
Advanced Drug Delivery Reviews 107: 176-191.
- Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC et al.
(2000). VEGF gene delivery to myocardium: deleterious effects
of unregulated expression. Circulation 102: 898-901.
- Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989).
Vascular endothelial growth factor is a secreted angiogenic
mitogen. Science 246: 1306-1309.
- Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H et al.
(2002). Increased vascularity detected by digital subtraction
angiography after VEGF gene transfer to human lower limb
artery: a randomized, placebo-controlled, double-blinded
phase II study. Molecular Therapy 6: 127-133.
- Mezu-Ndubuisi OJ, Wang Y, Schoephoerster J, Falero-Perez J, Zaitoun
IS et al. (2019). Intravitreal Delivery of VEGF-A165-loaded
PLGA Microparticles Reduces Retinal Vaso-Obliteration in an
In Vivo Mouse Model of Retinopathy of Prematurity. Current
Eye Research 44: 275-286.
- Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC et al.
(1997). Vascular endothelial growth factor: crystal structure
and functional mapping of the kinase domain receptor binding
site. Proceedings of the National Academy of Sciences of the
United States of America 94: 7192-7197.
- Nakatsu MN, Sainson RC, Perez del Pulgar S, Aoto JN, Aitkenhead
M et al. (2003). VEGF (121) and VEGF (165) regulate blood
vessel diameter through vascular endothelial growth factor
receptor 2 in an in vitro angiogenesis model. Lab Invest 83
(12): 1873-1885.
- Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M
et al. (2010). Regulation of vascular endothelial growth factor
(VEGF) splicing from pro-angiogenic to anti-angiogenic
isoforms: a novel therapeutic strategy for angiogenesis. Journal
of Biological Chemistry 285: 5532-5540.
- Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D et al. (2006).
Human umbilical vein endothelial cells and human dermal
microvascular endothelial cells offer new insights into the
relationship between lipid metabolism and angiogenesis. Stem
Cell Reviews and Reports 2: 93-102.
- Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI
et al. (2003). Fibroblast growth factor 4 induces vascular
permeability, angiogenesis and arteriogenesis in a rabbit
hindlimb ischemia model. Federation of American Societies
for Experimental Biology 17: 100-102.
- Rosano GL, Ceccarelli EA (2014). Recombinant protein expression
in Escherichia coli: advances and challenges. Frontiers in
Microbiology 5: 172
- Rui J, Dadsetan M, Runge MB, Spinner RJ, Yaszemski MJ et al.
(2012). Controlled release of vascular endothelial growth
factor using poly-lactic-co-glycolic acid microspheres: in vitro
characterization and application in polycaprolactone fumarate
nerve conduits. Acta Biomaterialia 8: 511-518
- Saini V, Verma SK, Sahoo MK, Kohli DV, Murthy PK (2011).
Sufficiency of a single administration of filarial antigens
adsorbed on polymeric lamellar substrate particles of poly
(L-lactide) for immunization. International Journal of
Pharmaceutics 420: 101-110
- Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS et al.
(1983). Tumor cells secrete a vascular permeability factor that
promotes accumulation of ascites fluid. Science 219: 983-985
- Sharkey AM, Day K, McPherson A, Malik S, Licence D et al. (2000).
Vascular endothelial growth factor expression in human
endometrium is regulated by hypoxia. Journal of Clinical
Endocrinology and Metabolism 85: 402-409
- Shibuya M (2011). Vascular Endothelial Growth Factor (VEGF) and
its receptor (VEGFR) signaling in angiogenesis: A crucial target
for anti- and pro-angiogenic therapies. Genes and Cancer 2:
1097-1105
- Shibuya M, Claesson-Welsh L (2006). Signal transduction by VEGF
receptors in regulation of angiogenesis and lymphangiogenesis.
Experimental Cell Research 312: 549-560
- Simamora P, Chern W (2006). Poly-L-lactic acid: an overview.
Journal of Drugs in Dermatology 5: 436-440
- Simons M, Annex BH, Laham RJ, Kleiman N, Henry T et al.
(2002). Pharmacological treatment of coronary artery disease
with recombinant fibroblast growth factor-2: double-blind,
randomized, controlled clinical trial. Circulation 105: 788-793
- Smith SK (2001). Regulation of angiogenesis in the endometrium.
Trends in Endocrinology & Metabolism 12: 147-151
- Taktak-Ben Amar A, Morjen M, Ben Mabrouk H, AbdelmaksoudDammak R, Guerfali M et al. (2017). Expression, purification
and functionality of bioactive recombinant human vascular
endothelial growth factor VEGF165 in E. coli. Applied
Microbiology and Biotechnology 7: 33
- Tonks AJ, Cooper RA, Jones KP, Blair S, Parton J, Tonks A (2003).
Honey stimulates inflammatory cytokine production from
monocytes. Cytokine 21(5): 242-247.
- Walsh K, Sriprasad S, Hopster D, Codd J, Mulvin D (2002).
Distribution of vascular endothelial growth factor (VEGF) in
prostate disease. Prostate Cancer and Prostatic Diseases 5: 119-
122
- Wimasis, 2016a. WimCAM: CAM Assay Image Analysis Solution.
Release 1.1. Available at: https://www.wimasis.com/en/
products/2/WimCAM
- Wimasis, 2016b. WimTube: Tube Formation Assay Image Analysis
Solution. Release 4.0. Available at: https://www.wimasis.com/
en/products/13/WimTube
- Xin H, Zhong C, Nudleman E, Ferrara N (2016). Evidence for proangiogenic functions of VEGF-Ax. Cell 167: 275-284.